

**Table 1. Seizure-freedom rates during the Maintenance Periods in Studies 342 and 412 in patients with SGS**

<b>Perampanel dose</b>	<b>Study 342 Seizure-freedom rate<sup>a</sup> in patients receiving perampanel monotherapy, n (%) [95% CI]</b>	<b>Study 412 Seizure-freedom rate<sup>b</sup> in patients receiving perampanel as add-on therapy, n (%) [95% CI]</b>
4 mg/day (n=48)	31 (64.6) [49.5, 77.8]	—
4 or 8 mg/day (n=48)	37 (77.1) [62.7, 88.0]	—
Up to 12 mg/day (n=16)	—	12 (75.0%) [47.6, 92.7]

<sup>a</sup>Seizure-freedom rates are for SGS

<sup>b</sup>Seizure-freedom rates are for all POS types

CI, confidence interval; POS, partial-onset seizures; SGS, secondarily generalized seizures